STAAR Surgical Company (FRA:SR3)
Germany · Delayed Price · Currency is EUR | Market Cap | 768.86M -2.7% |
| Revenue (ttm) | 203.86M -23.7% |
| Net Income | -68.49M |
| EPS | -1.38 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 34.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 184 |
| Open | 16.10 |
| Previous Close | 16.38 |
| Day's Range | 16.10 - 16.10 |
| 52-Week Range | 13.44 - 24.46 |
| Beta | n/a |
| RSI | 52.03 |
| Earnings Date | May 12, 2026 |
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers... [Read more]
Financial Performance
In fiscal year 2025, STAAR Surgical Company's revenue was $239.44 million, a decrease of -23.72% compared to the previous year's $313.90 million. Losses were -$80.45 million, 298.1% more than in 2024.
Financial numbers in USD Financial StatementsNews
STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript
STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript
STAAR Surgical Issues Shareholder Letter
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) ...
STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board Influence
STAAR Surgical Company (NASDAQ: STAA) shares are down on Thursday as the company is undergoing significant board changes.
STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) ...
Alcon Terminates Agreement to Acquire STAAR Surgical
GENEVA--(BUSINESS WIRE)--Alcon Terminates Agreement to Acquire STAAR Surgical.
STAAR Surgical Merger With Alcon Fails After Shareholders Vote No
STAAR Surgical Company (NASDAQ: STAA) announced Tuesday that it did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. (NYSE: ALC) at the Special Meeting of St...
Broadwood Partners Comments on STAAR Surgical Shareholders' Rejection of the Company's Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Compan...
Staar Surgical to reject Alcon takeover bid after failing to win shareholder backing
STAAR Surgical said on Tuesday it plans to terminate its merger agreement with Swiss eyecare giant Alcon after failing to secure enough shareholder votes to approve the deal, sending its shares down m...
STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
Broadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Compan...
Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right...
Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised Deal CHARLOTTE, N.C. , Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareh...
Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on a report published by Institutional Shareholder Services Inc. (“ISS”), an independent pr...
Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, ha...
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...